These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 29913237

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z, Wu J, Dang H, Lin H, Zheng H, Zhong D.
    Cancer Lett; 2011 Apr 28; 303(2):92-8. PubMed ID: 21330050
    [Abstract] [Full Text] [Related]

  • 3. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H.
    Theranostics; 2021 Apr 28; 11(5):2108-2122. PubMed ID: 33500714
    [Abstract] [Full Text] [Related]

  • 4. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
    Li S, Peng F, Ning Y, Jiang P, Peng J, Ding X, Zhang J, Jiang T, Xiang S.
    J Cell Biochem; 2020 Mar 28; 121(3):2543-2558. PubMed ID: 31696971
    [Abstract] [Full Text] [Related]

  • 5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017 Mar 28; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 28; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 7. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
    Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P, Poon RT.
    Clin Cancer Res; 2008 Nov 01; 14(21):6813-20. PubMed ID: 18980975
    [Abstract] [Full Text] [Related]

  • 8. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC, Wasser S, Tan T, Lim SG.
    World J Gastroenterol; 2012 Jul 21; 18(27):3527-36. PubMed ID: 22826617
    [Abstract] [Full Text] [Related]

  • 9. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
    Ito T, Sato F, Kan T, Cheng Y, David S, Agarwal R, Paun BC, Jin Z, Olaru AV, Hamilton JP, Selaru FM, Yang J, Matsumura N, Shimizu K, Abraham JM, Shimada Y, Mori Y, Meltzer SJ.
    Int J Cancer; 2011 Nov 01; 129(9):2134-46. PubMed ID: 21170987
    [Abstract] [Full Text] [Related]

  • 10. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M, Quaas M, Nickel A, Engeland K.
    Oncotarget; 2015 Dec 08; 6(39):41402-17. PubMed ID: 26595675
    [Abstract] [Full Text] [Related]

  • 11. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.
    Br J Cancer; 2017 Apr 11; 116(8):1027-1036. PubMed ID: 28267710
    [Abstract] [Full Text] [Related]

  • 12. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
    Li L, Huang K, Zhao H, Chen B, Ye Q, Yue J.
    Cell Cycle; 2020 May 11; 19(10):1236-1252. PubMed ID: 32275843
    [Abstract] [Full Text] [Related]

  • 13. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
    Studach LL, Rakotomalala L, Wang WH, Hullinger RL, Cairo S, Buendia MA, Andrisani OM.
    Hepatology; 2009 Aug 11; 50(2):414-23. PubMed ID: 19472310
    [Abstract] [Full Text] [Related]

  • 14. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
    Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S.
    Oncogene; 2012 Oct 18; 31(42):4517-26. PubMed ID: 22249248
    [Abstract] [Full Text] [Related]

  • 15. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
    Chen XJ, Wu LM, Xu XB, Feng XW, Xie HY, Zhang M, Shen Y, Wang WL, Liang TB, Zheng SS.
    Zhonghua Wai Ke Za Zhi; 2007 Oct 01; 45(19):1354-8. PubMed ID: 18241575
    [Abstract] [Full Text] [Related]

  • 16. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B.
    Gastroenterology; 2012 Sep 01; 143(3):811-820.e15. PubMed ID: 22641068
    [Abstract] [Full Text] [Related]

  • 17. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2.
    Chen F, Chen C, Yang S, Gong W, Wang Y, Cianflone K, Tang J, Wang DW.
    PLoS One; 2012 Sep 01; 7(6):e39197. PubMed ID: 22761738
    [Abstract] [Full Text] [Related]

  • 18. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
    Jeong SB, Im JH, Yoon JH, Bui QT, Lim SC, Song JM, Shim Y, Yun J, Hong J, Kang KW.
    Mol Cancer Ther; 2018 Apr 01; 17(4):825-837. PubMed ID: 29437878
    [Abstract] [Full Text] [Related]

  • 19. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
    Xu C, Li S, Chen T, Hu H, Ding C, Xu Z, Chen J, Liu Z, Lei Z, Zhang HT, Li C, Zhao J.
    Oncol Rep; 2016 Jan 01; 35(1):497-503. PubMed ID: 26549165
    [Abstract] [Full Text] [Related]

  • 20. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B, Wang R, Chen LB.
    Cancer Lett; 2012 Apr 28; 317(2):184-91. PubMed ID: 22120675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.